Successful Permanent Correction of 'Familial Dysautonomia' Gene Defect Using Prime Editing
-
Cause of Familial Dysautonomia (FD): This rare, life-threatening autosomal recessive neuropathy arises in approximately 99.8% of cases due to the c.2204+6T>C intronic mutation within the ELP1/IKAP gene. This mutation disrupts normal splicing by causing exon 20 skipping, thereby impairing ELP1 protein production. Current treatments offer only temporary symptom relief, underscoring the urgent need for permanent genetic correction.
-
Innovative Approach: Researchers leveraged Prime Editing (PE3), a next-generation gene editing tool, to achieve permanent correction of this genetic defect. PE3 enables precise editing without fully severing DNA strands, facilitating targeted base modifications or insertions.
- Enhanced Efficiency: Compared to previous iterations (PE2), PE3 significantly boosted exon 20 inclusion rates from an initial 19% to approximately 60%.
- Alternative Strategy Success: By precisely modifying an enhancer sequence (ESS2), researchers achieved an additional 50% recovery rate.
-
Significant Milestone: Achieving a genomic editing efficiency of roughly 10% with PE3 represents a groundbreaking advancement. Given that even modest enhancements in ELP1 expression levels (5-10% compared to wild-type) substantially alleviate FD symptoms in preclinical models, this correction efficiency heralds substantial clinical promise.
-
Future Directions: This study validates Prime Editing as a potent therapeutic modality for complex splicing disorders like FD. Future endeavors will focus on advancing in vivo gene correction studies to offer permanent treatment options for FD patients.
Familial Dysautonomia (FD; OMIM #223900) is characterized by a nearly universal (99.8%) occurrence of FD due to the c.2204+6T>C intronic mutation in the ELP1/IKAP gene, leading to exon 20 skipping and reduced ELP1 protein levels. Although splicing modulation therapies have shown partial efficacy, permanent genetic correction remains unattainable. This study presents the first application of Prime Editing (PE) to rectify the splicing defect responsible for FD. Utilizing a mutant exon-trapping minigene (pTB-IKAP) transiently transfected with PE2 or PE3 components in HEK293T cells, we observed a substantial increase in exon 20 inclusion from 19 ± 2% to 48 ± 3% and further to 60 ± 3% with PE3. Genetic validation through restriction fragment length polymorphism analysis and Sanger sequencing confirmed allele correction, achieving approximately 10% genomic editing efficiency with PE3. Additionally, targeting ESS2 via a silent A>G substitution restored exon inclusion to 50 ± 4%. These findings establish PE3, particularly, as a highly effective strategy for correcting or bypassing the c.2204+6T>C mutation and restoring proper splicing in FD. Considering that modest increases in ELP1 expression (5-10% of wild-type levels) significantly alleviate FD severity in animal models, our results underscore PE3 as a promising curative approach, paving the way for future ex vivo and in vivo therapeutic applications.
Prime Editing offers a durable genetic correction method, potentially revolutionizing treatment for FD and similar rare diseases by addressing root causes rather than merely managing symptoms. This could dramatically enhance patient quality of life and reduce healthcare costs.